Quantitative Evaluation of Multiple Treatment Regimens for Treatment-resistant Depression

Overview

Journal Int J Neuropsychopharmacol

Publisher Oxford University Press

Date 2025 Jan 25

PMID 39862179

Authors

Yulin Feng

Yinghua Lv

Juan Yang

Ling Xu

Junchao Chen

Jihan Huang

Jiyuan Ren

Qingshan Zheng

Lujin Li

Affiliations

Soon will be listed here.

Abstract

Objective: This study aims to quantitatively evaluate the efficacy and safety of various treatment regimens for treatment-resistant depression (TRD) across oral, intravenous, and intranasal routes to inform clinical guidelines.

Methods: A systematic review identified randomized controlled trials on TRD, with efficacy measured by changes in the Montgomery-Åsberg Depression Rating Scale (MADRS). We developed pharmacodynamic and covariate models for different administration routes, using Monte Carlo simulations to estimate efficacy distribution. Dropout and adverse event-related dropout rates were analyzed via single-arm meta-analysis.

Results: Involving 22 studies with 56 treatment arms and 3059 patients, our findings suggest combination therapies outperform monotherapy, achieving an additional 6.5% reduction in MADRS scores over 12 weeks. The most effective combinations were olanzapine with fluoxetine and quetiapine with selective serotonin reuptake inhibitors/ selective serotonin and norepinephrine reuptake inhibitors. Injectable treatments, particularly ayahuasca, produced rapid effects, with a 77% reduction in MADRS scores at 15 days. Intranasal treatments reached efficacy sooner than oral ones, with 28-day efficacy similar to the 12-week efficacy of the olanzapine-fluoxetine combination. Dropout rates due to adverse events were similar across methods (4.5%-5.2%), but total dropouts were highest for oral (17.9%) and lowest for intranasal routes (10.6%). Additionally, there was considerable variation in the incidence of headache, dizziness, and nausea across different administration routes.

Conclusions: The quantitative evaluation of 22 TRD treatments illuminates key pharmacodynamic parameters, bolstering the development of clinical guidelines and aiding the design of clinical trials and medical decision-making.

References

Kin K, Yasuhara T, Kawauchi S, Kameda M, Hosomoto K, Tomita Y . Lithium counteracts depressive behavior and augments the treatment effect of selective serotonin reuptake inhibitor in treatment-resistant depressed rats. Brain Res. 2019; 1717:52-59. DOI: 10.1016/j.brainres.2019.04.001. View

Lin C, Lin S, Jang F . Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study. J Clin Psychopharmacol. 2011; 31(5):563-8. DOI: 10.1097/JCP.0b013e31822bb0db. View

Fava M, Freeman M, Flynn M, Judge H, Hoeppner B, Cusin C . Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2018; 25(7):1592-1603. PMC: 6447473. DOI: 10.1038/s41380-018-0256-5. View

Hieronymus F, Lisinski A, Eriksson E, Ostergaard S . Do side effects of antidepressants impact efficacy estimates based on the Hamilton Depression Rating Scale? A pooled patient-level analysis. Transl Psychiatry. 2021; 11(1):249. PMC: 8079707. DOI: 10.1038/s41398-021-01364-0. View

Ivan Ezquerra-Romano I, Lawn W, Krupitsky E, Morgan C . Ketamine for the treatment of addiction: Evidence and potential mechanisms. Neuropharmacology. 2018; 142:72-82. DOI: 10.1016/j.neuropharm.2018.01.017. View

Kasper S, Tauscher J, Heiden A . Quetiapine: efficacy and tolerability in schizophrenia. Eur Neuropsychopharmacol. 2001; 11 Suppl 4:S405-13. DOI: 10.1016/s0924-977x(01)00111-0. View

Chouinard G, Samaha A, Chouinard V, Peretti C, Kanahara N, Takase M . Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy. Psychother Psychosom. 2017; 86(4):189-219. DOI: 10.1159/000477313. View

Boucher M, Bennetts M . The Many Flavors of Model-Based Meta-Analysis: Part I-Introduction and Landmark Data. CPT Pharmacometrics Syst Pharmacol. 2016; 5(2):54-64. PMC: 4761229. DOI: 10.1002/psp4.12041. View

Palhano-Fontes F, Barreto D, Onias H, Andrade K, Novaes M, Pessoa J . Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2018; 49(4):655-663. PMC: 6378413. DOI: 10.1017/S0033291718001356. View

10.

Cleare A, Pariante C, Young A, Anderson I, Christmas D, Cowen P . Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015; 29(5):459-525. DOI: 10.1177/0269881115581093. View

11.

Caldiroli A, Capuzzi E, Tagliabue I, Capellazzi M, Marcatili M, Mucci F . Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review. Int J Mol Sci. 2021; 22(23). PMC: 8658307. DOI: 10.3390/ijms222313070. View

12.

Bobo W, Shelton R . Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression. Expert Rev Neurother. 2010; 10(5):651-70. DOI: 10.1586/ern.10.44. View

13.

Bschor T, Bauer M . Efficacy and mechanisms of action of lithium augmentation in refractory major depression. Curr Pharm Des. 2006; 12(23):2985-92. DOI: 10.2174/138161206777947650. View

14.

Dodd S, Berk M . Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility. Expert Rev Neurother. 2008; 8(9):1299-306. DOI: 10.1586/14737175.8.9.1299. View

15.

Amsterdam J, Shults J . MAOI efficacy and safety in advanced stage treatment-resistant depression--a retrospective study. J Affect Disord. 2005; 89(1-3):183-8. DOI: 10.1016/j.jad.2005.06.011. View

16.

Ebert D, Albert R, May A, Stosiek I, Kaschka W . Combined SSRI-RIMA treatment in refractory depression. Safety data and efficacy. Psychopharmacology (Berl). 1995; 119(3):342-4. DOI: 10.1007/BF02246301. View

17.

Nguyen T, Mouksassi M, Holford N, Al-Huniti N, Freedman I, Hooker A . Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics. CPT Pharmacometrics Syst Pharmacol. 2016; 6(2):87-109. PMC: 5321813. DOI: 10.1002/psp4.12161. View

18.

Dominguez-Clave E, Soler J, Elices M, Pascual J, Alvarez E, de la Fuente Revenga M . Ayahuasca: Pharmacology, neuroscience and therapeutic potential. Brain Res Bull. 2016; 126(Pt 1):89-101. DOI: 10.1016/j.brainresbull.2016.03.002. View

19.

Fedgchin M, Trivedi M, Daly E, Melkote R, Lane R, Lim P . Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Int J Neuropsychopharmacol. 2019; 22(10):616-630. PMC: 6822141. DOI: 10.1093/ijnp/pyz039. View

20.

Galecki P, Samochowiec J, Mikulowska M, Szulc A . Treatment-Resistant Depression in Poland-Epidemiology and Treatment. J Clin Med. 2022; 11(3). PMC: 8837165. DOI: 10.3390/jcm11030480. View